Stock Analysis

Talbros Automotive Components Third Quarter 2025 Earnings: EPS: ₹3.86 (vs ₹3.69 in 3Q 2024)

NSEI:TALBROAUTO
Source: Shutterstock

Talbros Automotive Components (NSE:TALBROAUTO) Third Quarter 2025 Results

Key Financial Results

  • Revenue: ₹2.01b (up 1.4% from 3Q 2024).
  • Net income: ₹238.2m (up 4.7% from 3Q 2024).
  • Profit margin: 12% (in line with 3Q 2024).
  • EPS: ₹3.86 (up from ₹3.69 in 3Q 2024).
earnings-and-revenue-history
NSEI:TALBROAUTO Earnings and Revenue History February 13th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Talbros Automotive Components shares are down 11% from a week ago.

Risk Analysis

It is worth noting though that we have found 1 warning sign for Talbros Automotive Components that you need to take into consideration.

Valuation is complex, but we're here to simplify it.

Discover if Talbros Automotive Components might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NSEI:TALBROAUTO

Talbros Automotive Components

Engages in the manufacture and sale of auto components in India.

Flawless balance sheet with proven track record.

Community Narratives

AstraZeneca's Oncology and Obesity Innovations Will Drive Revenue Growth by 10%
Fair Value SEK 2.55k|37.11% undervalued
Unike
Unike
Community Contributor
Leading the Charge in SME SaaS Innovation
Fair Value SEK 100.02|23.535% undervalued
Investingwilly
Investingwilly
Community Contributor
Brookfield Corporation is a solid BUY for a long-term portfolio
Fair Value CA$82.23|1.7389999999999999% overvalued
Jonataninho
Jonataninho
Community Contributor